Biora Therapeutics Inc (BIOR) - Total Assets
Based on the latest financial reports, Biora Therapeutics Inc (BIOR) holds total assets worth $14.51 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Biora Therapeutics Inc's book value for net asset value and shareholders' equity analysis.
Biora Therapeutics Inc - Total Assets Trend (2018–2023)
This chart illustrates how Biora Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Biora Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Biora Therapeutics Inc's total assets of $14.51 Million consist of 61.1% current assets and 38.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.7% |
| Accounts Receivable | $830.00K | 2.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $6.07 Million | 19.5% |
Asset Composition Trend (2018–2023)
This chart illustrates how Biora Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biora Therapeutics Inc (BIOR) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biora Therapeutics Inc's current assets represent 61.1% of total assets in 2023, a decrease from 76.4% in 2018.
- Cash Position: Cash and equivalents constituted 48.7% of total assets in 2023, up from 42.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 9.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 19.5% of total assets.
Biora Therapeutics Inc Competitors by Total Assets
Key competitors of Biora Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC
|
USA | $5.99 Billion |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $584.09 Million |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Biora Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.28 | 0.74 |
| Quick Ratio | 0.05 | 0.19 | 0.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-114.56 Million | $-50.30 Million | $-25.69 Million |
Biora Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Biora Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -41.7% |
| Total Assets | $31.21 Million |
| Market Capitalization | $994.99K USD |
Valuation Analysis
Below Book Valuation: The market values Biora Therapeutics Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biora Therapeutics Inc's assets decreased by 41.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biora Therapeutics Inc (2018–2023)
The table below shows the annual total assets of Biora Therapeutics Inc from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $31.21 Million | -41.68% |
| 2022-12-31 | $53.52 Million | -50.82% |
| 2021-12-31 | $108.84 Million | -29.53% |
| 2020-12-31 | $154.44 Million | +51.82% |
| 2019-12-31 | $101.73 Million | -12.60% |
| 2018-12-31 | $116.40 Million | -- |
About Biora Therapeutics Inc
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more